ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of their interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explained why time savings dominates the eNPV model for RBQM and what that means for how sponsors should frame the internal case for investment. Phase duration reductions and earlier database lock drive the largest financial impact, shifting how sponsors prioritize which operational improvements matter most.
• The FDA reaffirmed that Good Clinical Practice standards apply equally to all trials regardless of geography, and senior leaders outlined concrete steps to expand foreign inspection coverage, update risk-based inspection criteria, and enhance reviewer training on data integrity. When the FDA cannot validate that data were collected in compliance with standards, regulations allow the agency to refuse to accept such evidence in support of a marketing application.
• In an interview from Pharmaceutical Executive, Mark Cziraky, president of Carelon Research, discussed the mechanics of analyzing linked data sets within trusted research environments versus de-identified flat files. The analytical rigor remains constant, but data governance models fundamentally change what happens before analysis begins—the volume and richness of available data, acquisition processes, and the evidence quality that ultimately results.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.